Why AbbVie Inc. (ABBV) stock moved
AbbVie Inc. (ABBV) shares rose 1.5% to $276.47 as of October 10, 2026, a modest gain from the prior close of $272.42. BestStocks flagged the session as a material change for ABBV. The move is tied to company news. Below, we break down what changed for ABBV, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
AbbVie's Temab-A cancer drug receives two FDA Breakthrough Therapy designations for colorectal and lung cancers. Accelerated development pathway could enable faster market entry for high-potential oncology asset, supporting revenue growth.
What it means for AbbVie Inc. investors
For AbbVie Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.5% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in ABBV's fundamentals. Wall Street's consensus price target sits at $292.21, implying +5.7% upside from $276.47. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality weak (31/100). With earnings roughly 20 days out, the next report is the most likely near-term test of the move.
ABBV price reaction
ABBV last traded at $276.47, up $4.05 (+1.49%) from the previous close of $272.42. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +1.9% over the same stretch, leaving ABBV essentially in line with peers. Over the past month the stock has ranged between $250.91 and $276.47, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on AbbVie Inc. (ABBV)
The consensus analyst price target on AbbVie Inc. (ABBV) is $292.21, 5.7% above the recent $276.47. Over the past 90 days analysts logged 2 upgrades, 23 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ABBV line up.
The bullish case
- Wall Street's consensus price target of $292.21 implies +5.7% upside from $276.47.
- The Street's most bullish target is $320.00 (+15.7%).
- 2 analyst upgrades in the past 90 days, most recently Wolfe Research to Outperform (2026-08-13).
- Positive 1.5% session move.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $235.00 (-15.0%).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ABBV
Frequently asked questions about ABBV
Why did AbbVie Inc. (ABBV) stock move?
ABBV rose 1.5% to $276.47. The move coincided with the context summarized above, which BestStocks classifies as a sector-wide move, though no single company-specific catalyst was independently confirmed.
How much did ABBV stock rise?
ABBV gained 1.49% ($4.05) versus the prior close of $272.42, last trading at $276.47 on 0.7× average volume.
When is AbbVie Inc.'s next earnings date?
ABBV's next earnings report is estimated for 2026-10-30 — about 20 days away.
What is the analyst price target for ABBV?
The consensus analyst price target for ABBV is $292.21, about 5.7% above the current $276.47. Over the past 90 days, analysts recorded 2 upgrades, 23 maintains, and 0 downgrades.
Is the ABBV move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +1.9% against ABBV's +1.5%. ABBV ranks top 6 of 7 peers.
How BestStocks tracks ABBV
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for ABBV, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.